Применение фиксированных комбинаций ингаляционных кортикостероидов и длительно действующих β₂-агонистов в лечении бронхиальной астмы

1. Adkins J.C., McTavish D. Salmeterol: a review of its pharmacological properties and clinical efficacy in management of children with asthma// Drugs.— 1997.— Vol.54.— P. 331— 354.

2. Bateman E.D., Britton М ., Carrillo J., et al. Salmelerol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma//Clin. Drug Invest.— 1998.— Vol.16.— P. 193—201.

3. Broaden R.N., Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease//Drugs.— 1991.— Vol.42P. 895—912.

4. Chapman K.R., Ringdal N„ Backer V., et al. Salmeterol and fluticasone propionate (50/250mcg) administered via combination Discus inhaler: as effective as when given via separate Diskus inhalers//Can. Respir. J.— 1999.— Vol.6, N .I.— P.45—51.

5. Chung K.F. The complementary role of glucocorticosteroids and long-acting (Vadrenergic agonists// Allergy.— 1998.— Vol. 53, Suppl.42.— P.7—13.

6. Coutts J.A.P., Gibson N.A., Paton J.Y. Measuring compliance with inhaled medication in asthma//Arch. Dis. Child.— 1992.— Vol.67.— P.332—333.

7. Dahl R. Salmeterol and fluticasone propionate in the treatment of asthma symptoms//Eur. Resp. Rev.— 1997.— №.7.— Vol.P. 338—343.

8. Davies B., Brooks G., Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine control stiudies//Respir. Med.— 1998.— Vol.92.— P.256— 263.

9. Edwards T., Gross G., Mitchell D., et al. The salmeterol xinafo-ate/fluticasone propionate dry powder combination product via Diskus inhaler improves asthma control compared to salmeterol xinafoate or fluticasone propionate alone [abstract]//Am. J. Respir. Crit. Care Med.— 1998.— Vo.157, (Pt2) Suppl., P.A414.

10. Eickelberg O., Roth M., Lorx R., et al. Ligand-independent actvation of the glucocorticoid receptor by p2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells//J. Biol. Chem.— 1999.— Vol.274, N.2.— P. 1005— 1010.

11. Green S.A., Spasoff A.P., Coleman R.A., et al. Sustained activation of a G protein-coupled receptor via 'anchored' agonist binding. Molecular localization of the salmeterol exosite within the p2-adrenergic receptor//J. Biol. Chem. 1996.— P. 2429—2435.

12. Greening A.P., Ind P.W., Northfield M., Allen&Hanburys Limited UK Study Group, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid//Lancet.— 1994.— Vol.344, №.8917.— P. 219—224.

13. Holliday S.M ., Faulds D., Sorkin L.M. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma//Drugs.— 1994.— Vol.47.— P.318— 331.

14. Ind P.W., Dal Negro R., Colman N., et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma II: exacerbations [abstract]// Am. J. Respir. Crit. Care Med.— 1998.— Vol.157 (Pt2), Suppl.— P. A415.

15. Ind P.W., Dal Negro R., Colman N., et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma I: lung function and symptoms [abstract]// Am. J. Respir. Crit. Care Med.— 1998.— Vol.157, (Pt2), Suppl.— P.A416.

16. Jack D. The use of inhaled p2 adrenergic hronchodilators and anti-inflammatory steroids in asthma// J. Pharmaceut. Med.— 1996.— Vol.6, №.1— 2.— P.5— 16.

17. Jarvis B., Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages <500 meg/day in adults and adolescents with mild to moderate asthma// Drugs.— 1999.— Vol.57.— P.769— 803.

18. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids// J. Allergy Clin. Immunol.— 1998.— Vol.101, (Part 2) Suppl.— P. 434—439.

19. Kalberg J.C., Yancey S., Emmett A.H., et al. A comparison of salmeterol versus zafirlucast in patients using inhaled corticosteroids [abstract]// J. Allergy Clin. Immunol.— 1999.— Vol.103.— P.S229.

20. Lumry W., Windom H., Mendelson L., et al. The salmeterol/fluticasone propionate (50/250mcg) dry powder combination Diskus has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma// J. Allergy Clin. Immunol.— 1999.— Vol. 103, Pt2.— P.132.

21. National Institutes of Health. Global initiative for asthma. Global strategy for asthma management and prevention N H LB/ WHO workshop report [online]. Global Initiative for Asthma and National Heart, Lung and Blood Institute; 1995 Jan. Available from: URL: http://www.ginasthma.com/workshop/default.html [Accessed 1999 May 5].

22. Pieters W.R., Steinmetz K.O., Aubier М., et al. Effectiveness of a new salmeterol/fluticasone propionate (50/500 meg) combination inhaler in patients with reversible airways obstruction [abstract]// Eur. Respir. J.— 1998.— Vol. 12, Suppl. 28.— P. 35s.

23. Reese P.R., Mahajan P., Woodring A. Salmeterol/fluticasone pro-pionate combination product improves quality of life in asthma patients [abstract]// Eur. Respir. J.— 1998.— Vol.12, Suppl. 28.— P.35s.

24. Reese P.R., Mather D.B., Mahajan P., et al. Combination of salmeterol/ flutica-sone propionate via Diskus improves quality of life in asthma patients [abstract]//J. Allergy Clin. Immunol.— 1999.— Vol.103, Pt2.— P.69.

25. Seretide. Monograph. Glaxo Wellcome UK. 1998.

26. Sly R.M. New guidelines for diagnosis and management of asthma/ / Ann. Allergy Asthma Immunol.— 1997.— Vol.78.— P.427—437.

27. Verberne A.A.P.H., Frost C., Duiverman E.J., et al. Addition of salmeterol versus doubling the dose of beclamethasone in children with asthma// Am. J. Respir. Crit. Care Med.— 1998 Vol.158.— P.213— 219.5p

28. Woolcock A., Lundback B., Ringdal N., et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids// Am. J. Respir. Crit. Care Med.— 1996.— Vol.153, N.5.— P.1481 — 1488.

29. Zimmerman B., Gold М., Wherrett D., et al. Adrenal suppression in two patients with asthma treated with low doses of the inhaled steroid fluticasone propionate// J. Allergy Clin. Immunol.— 1998.— Vol.101.— P.425— 426.